Published in Int J Clin Oncol on August 01, 2006
FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging (2009) 1.93
FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol (2010) 1.03
Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway. Am J Pathol (2007) 1.02
Batch-reactor microfluidic device: first human use of a microfluidically produced PET radiotracer. Lab Chip (2012) 0.97
Redox control of glutamine utilization in cancer. Cell Death Dis (2014) 0.93
Chicken or the egg: Warburg effect and mitochondrial dysfunction. F1000Prime Rep (2015) 0.91
Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). J Exp Clin Cancer Res (2008) 0.90
Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience. World J Surg Oncol (2011) 0.89
Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs (2008) 0.87
PET/CT: Current status in India. Indian J Radiol Imaging (2008) 0.85
Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med (2012) 0.85
Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [(18)F]ISO-1. PLoS One (2013) 0.83
124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. World J Surg Oncol (2010) 0.83
Staging primary head and neck cancers with (18)F-FDG PET/CT: is intravenous contrast administration really necessary? Eur J Nucl Med Mol Imaging (2009) 0.77
PET probes and oncological surgery: a productive new marriage for nuclear medicine? Eur J Nucl Med Mol Imaging (2007) 0.77
Does diabetes mellitus influence standardized uptake values of fluorodeoxyglucose positron emission tomography in colorectal cancer? Intest Res (2014) 0.76
Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer. Medicine (Baltimore) (2015) 0.76
Granuloma Mimicking Local Recurrence on PET/CT after Liver Resection of Colorectal Liver Metastasis: A Case Report. Cureus (2016) 0.75
Locally metastatic mucinous rectal adenocarcinoma: Imaging diagnosis with DW-MRI in comparison with PET-CT. Oncol Lett (2012) 0.75
Differentiation of malignant tumours from granulomas by using dynamic [(18)F]-fluoro-L-α-methyltyrosine positron emission tomography. EJNMMI Res (2015) 0.75
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med (2003) 7.64
Positron-emission tomography and assessment of cancer therapy. N Engl J Med (2006) 5.43
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA (2001) 5.10
A combined PET/CT scanner for clinical oncology. J Nucl Med (2000) 4.99
A tabulated summary of the FDG PET literature. J Nucl Med (2001) 4.37
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol (2005) 3.51
Clinical applications of PET in oncology. Radiology (2004) 3.44
Integrated PET/CT: current applications and future directions. Radiology (2006) 2.72
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol (2000) 2.58
Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med (2004) 2.55
Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol (2005) 2.54
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med (2002) 2.12
A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med (2000) 2.10
Clinical role of FDG PET in evaluation of cancer patients. Radiographics (2003) 2.08
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol (2005) 1.84
Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology (1998) 1.76
Utility of FDG-PET scanning in lymphoma by WHO classification. Blood (2003) 1.69
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol (2000) 1.69
The solitary pulmonary nodule. Radiology (2006) 1.54
Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med (2006) 1.52
18F-FDG PET detection of colonic adenomas. J Nucl Med (2001) 1.49
In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med (1995) 1.46
Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med (1994) 1.45
Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med (2006) 1.43
Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer (2000) 1.43
FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med (2001) 1.36
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood (1998) 1.32
Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med (2003) 1.32
18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med (2004) 1.31
Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg (1998) 1.30
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med (2005) 1.27
Role of positron emission tomography in lymphoma. J Clin Oncol (2005) 1.26
Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med (1998) 1.21
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer (2001) 1.19
The contribution of PET/CT to improved patient management. Br J Radiol (2006) 1.19
Initial and subsequent approach for the synthesis of 18FDG. Semin Nucl Med (2002) 1.18
The role of positron emission tomography in the management of bone metastases. Cancer (2000) 1.10
PET evaluation of lung cancer. J Nucl Med (2006) 1.08
The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med (2002) 1.08
18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med (2005) 0.99
Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest (2004) 0.91
The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg (2004) 0.87
Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg (2004) 0.86
Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest (2004) 0.84
Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer. Chest (2004) 0.83
18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut (2003) 0.81
Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol (2005) 0.80
Combined PET/CT colonography: is this the way forward? Gut (2006) 0.75
Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med (2004) 2.55
Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg (2004) 1.87
The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer (2005) 1.64
Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry Clin Neurosci (2006) 1.64
Thickening of the left atrial wall shortly after radiofrequency ablation predicts early recurrence of atrial fibrillation. Circ J (2010) 1.50
Esophageal anthracosis: lesion mimicking malignant melanoma. Pathol Int (2002) 1.46
FK506 controls CD40L-induced systemic autoimmunity in mice. J Invest Dermatol (2006) 1.42
Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest (2007) 1.41
l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci (2008) 1.37
Literature review of pain prevalence among older residents of nursing homes. Pain Manag Nurs (2010) 1.29
Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer (2002) 1.28
Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol (2010) 1.27
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer (2007) 1.23
Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood (2006) 1.23
Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol (2006) 1.22
Evaluation of hemangioma by positron emission tomography: role in a multimodality approach. J Comput Assist Tomogr (2003) 1.21
Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res (2010) 1.20
Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J Nucl Med (2007) 1.17
LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res (2011) 1.16
Pulmonary artery intimal sarcoma: the role of ¹⁸F-fluorodeoxyglucose positron emission tomography in monitoring response to treatment. Jpn J Radiol (2011) 1.11
HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res (2007) 1.09
Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res (2007) 1.07
CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol (2009) 1.07
The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer (2009) 1.07
Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas. Anticancer Res (2005) 1.06
Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging (2004) 1.05
Phosphorescent light-emitting iridium complexes serve as a hypoxia-sensing probe for tumor imaging in living animals. Cancer Res (2010) 1.03
Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci (2010) 1.02
Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med (2012) 1.02
The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology (Oxford) (2012) 1.01
Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med (2011) 1.00
¹⁸F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with ¹⁸F-FDG PET and immunohistochemistry. Ann Nucl Med (2010) 0.99
Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci (2008) 0.98
Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci (2009) 0.98
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer (2013) 0.97
Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci (2006) 0.97
L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology (2009) 0.96
Inverse correlation between tumor perfusion and glucose uptake in human head and neck tumors. Acad Radiol (2007) 0.96
Development of injectable O-15 oxygen and estimation of rat OEF. J Cereb Blood Flow Metab (2003) 0.96
Sentinel lymph nodes with technetium-99m colloidal rhenium sulfide in patients with esophageal carcinoma. Cancer (2003) 0.95
Peroxisome proliferator-activated receptor-γ in capillary endothelia promotes fatty acid uptake by heart during long-term fasting. J Am Heart Assoc (2013) 0.95
Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle. Arterioscler Thromb Vasc Biol (2013) 0.95
Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med (2005) 0.94
Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma. Histopathology (2014) 0.94
Augmented antibody response with premature germinal center regression in CD40L transgenic mice. J Immunol (2010) 0.94
Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem (2005) 0.94
L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res (2011) 0.93
Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer. Anticancer Res (2014) 0.93
Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT. J Nucl Med (2004) 0.93
Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res (2003) 0.92
Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol (2008) 0.91
Ectopic CD40 ligand expression on B cells triggers intestinal inflammation. J Immunol (2004) 0.91
Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract (2008) 0.91
A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma. Cancer Sci (2006) 0.91
Protective effect of zinc against ischemic neuronal injury in a middle cerebral artery occlusion model. J Pharmacol Sci (2006) 0.90
18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study. Eur J Radiol (2011) 0.90
Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg (2002) 0.90
Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography. Anticancer Res (2007) 0.90
Variability of lesion detectability and standardized uptake value according to the acquisition procedure and reconstruction among five PET scanners. Ann Nucl Med (2008) 0.90
Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer (2009) 0.90
Image Fusion System Using PACS for MRI, CT, and PET Images. Clin Positron Imaging (1999) 0.89
Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Sci (2014) 0.88
Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. Cancer Sci (2009) 0.88
Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci (2008) 0.88
Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer (2012) 0.87
An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice. J Immunol (2005) 0.87
Three-dimensional visualization of the coronary venous system using multidetector row computed tomography. Circ J (2005) 0.87
Dual functional molecular imaging probe targeting CD20 with PET and optical imaging. Oncol Rep (2009) 0.87
Role of F-18 FDG PET/CT in assessing IgG4-related disease with inflammation of head and neck glands. Ann Nucl Med (2015) 0.87
Lack of evidence for apoptosis as a cause of delayed onset paraplegia after spinal cord ischemia in rabbits. Anesth Analg (2003) 0.87
Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Ann Nucl Med (2008) 0.86
Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. Exp Dermatol (2008) 0.86
Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatol Res (2014) 0.86
Oncological diagnosis using (11)C-choline-positron emission tomography in comparison with 2-deoxy-2-[(18)F] fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2004) 0.86
Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Cancer Sci (2011) 0.86